Finance

Lists
Why is KYTX down 4,60%?
Dive Deeper
KYTX:NASDAQ
Kyverna Therapeutics Inc
US$6,22
-4,60%
(-0,30) 1D
US$6,25
+0,48% (+0,030)
After hours
Closed: 2 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
US$6,62
High
US$6,75
Low
US$6,17
Mkt. cap
384,67 ລ້ານ
Avg. vol.
862,64 ພັນ
Volume
1,18 ລ້ານ
52-wk high
US$13,67
52-wk low
US$5,30
EPS
US$-2,94
Shares outstanding
61,84 ລ້ານ
No. of employees
149
Open
US$6,62
High
US$6,75
Low
US$6,17
Mkt. cap
384,67 ລ້ານ
Avg. vol.
862,64 ພັນ
Volume
1,18 ລ້ານ
52-wk high
US$13,67
52-wk low
US$5,30
EPS
US$-2,94
Shares outstanding
61,84 ລ້ານ
No. of employees
149
News stories
From web sources and news partners
About Kyverna Therapeutics Inc
CEO-
Employees149
Founded2018
HeadquartersEmeryville, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitekyvernatx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current US$6,22
US$33,00 (+430,55%)
Average
US$30,33 (+387,62%)
Lowest
US$25,00 (+301,93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
US$25,00
+301,9%
09/25/2026
Derek Archila
Wells Fargo
Buy
Reiterated
US$33,00
+430,5%
09/25/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/24/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
US$33,00
+430,5%
08/12/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/12/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
US$29,00
+366,2%
05/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
US$30,00
+382,3%
03/30/2026
Last report
11 ສ.ຫ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
US$-0,63 / US$-0,68
+7,28%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
-
-
-
-
Cost of goods sold
30,46 ລ້ານ
-103,71 ລ້ານ
30,07 ລ້ານ
-
Cost of revenue
30,46 ລ້ານ
-103,71 ລ້ານ
30,07 ລ້ານ
-
Research and development expenses
-
133,72 ລ້ານ
-
24,79 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,27 ລ້ານ
9,27 ລ້ານ
11,29 ລ້ານ
14,77 ລ້ານ
Operating expense
8,27 ລ້ານ
142,99 ລ້ານ
11,29 ລ້ານ
39,56 ລ້ານ
Total operating expenses
38,73 ລ້ານ
39,28 ລ້ານ
41,37 ລ້ານ
39,56 ລ້ານ
Operating income
-38,73 ລ້ານ
-39,28 ລ້ານ
-41,37 ລ້ານ
-39,56 ລ້ານ
Other non operating income
-53,00 ພັນ
17,00 ພັນ
-21,00 ພັນ
-18,00 ພັນ
EBT including unusual items
-36,79 ລ້ານ
-37,80 ລ້ານ
-39,73 ລ້ານ
-38,32 ລ້ານ
EBT excluding unusual items
-36,79 ລ້ານ
-37,80 ລ້ານ
-39,73 ລ້ານ
-38,32 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36,79 ລ້ານ
-37,80 ລ້ານ
-39,73 ລ້ານ
-38,32 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-0,85
-0,80
-0,66
-0,63
Interest and investment income
2,00 ລ້ານ
1,90 ລ້ານ
2,33 ລ້ານ
1,93 ລ້ານ
Interest expense
-7,00 ພັນ
-444,00 ພັນ
-667,00 ພັນ
-674,00 ພັນ
Net interest expenses
1,99 ລ້ານ
1,46 ລ້ານ
1,66 ລ້ານ
1,26 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-37,84 ລ້ານ
-38,91 ລ້ານ
-41,02 ລ້ານ
-39,12 ລ້ານ
Gain or loss from assets sale
40,00 ພັນ
20,00 ພັນ
-
-47,00 ພັນ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
ແອັບຂອງ Google